Denali Therapeutics (DNLI) EBT Margin (2018 - 2026)
Denali Therapeutics (DNLI) posted quarterly EBT Margin of 7841.59% for Q3 2023, down 478088.0% year-over-year from N/an in Q3 2022, and down 12676.92% quarter-over-quarter from 62.35% in Q2 2023.
Denali Therapeutics (DNLI) EBT Margin (2018 - 2026) Analysis & Trends
Denali Therapeutics (DNLI) has reported EBT Margin for 6 consecutive years, with 7841.59% the latest figure, recorded in Q3 2023.
- In Q3 2023, EBT Margin fell 478088.0% year-over-year to 7841.59%; the TTM figure through Jun 2024 stood at 33565.19% (down 3352685.0% YoY), while the FY2023 annual figure was 43.93%, up 26633.0% from the prior year.
- EBT Margin fell to 7841.59% in Q3 2023 per DNLI's latest filing, from 62.35% in the prior quarter.
- Across five years, EBT Margin topped out at 77.56% in Q4 2020 and bottomed at 109419.23% in Q1 2020.
- Historically, EBT Margin has averaged 7027.02% across 5 years, with a median of 927.28% in 2019.
- Annual changes were most pronounced in 2020 — EBT Margin slumped 10849195 bps — and 2021, when it jumped 10853510 bps.
- Denali Therapeutics' EBT Margin stood at 3648.78% in 2019, then jumped by 102 bps to 77.56% in 2020, then slumped by 301 bps to 155.87% in 2021, then slumped by 533 bps to 986.84% in 2022, then slumped by 695 bps to 7841.59% in 2023.
- Business Quant data shows DNLI's EBT Margin at 7841.59% in Q3 2023, 62.35% in Q2 2023, and 320.93% in Q1 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 34.77% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 18.33% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -94.22% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.77% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -2.67% |
| 10 | Denali Therapeutics | 3.90 Bn | 3.90 Bn | 3.51 Mn | -3,622.45% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3,622.45% |
| Sep 30, 2023 | -7,841.59% |
| Jun 30, 2023 | 62.35% |
| Mar 31, 2023 | -320.93% |
| Dec 31, 2022 | -986.84% |
| Sep 30, 2022 | -3,060.71% |
| Jun 30, 2022 | -111.98% |
| Mar 31, 2022 | -164.01% |
| Dec 31, 2021 | -155.87% |
| Sep 30, 2021 | -1,600.53% |
| Jun 30, 2021 | -404.61% |
| Mar 31, 2021 | -884.13% |
| Dec 31, 2020 | 77.56% |
| Sep 30, 2020 | -619.64% |
| Jun 30, 2020 | -1,009.79% |
| Mar 31, 2020 | -109,419.23% |
| Dec 31, 2019 | -3,648.78% |
| Sep 30, 2019 | -1,066.15% |
| Jun 30, 2019 | -1,431.19% |
| Mar 31, 2019 | -927.28% |